Therefore, STAT3 knockdown, administration of certain small molecule inhibitors, or CCL5 blockade by using neutralizing antibody in combination with the conventional Doc treatment may provide a new therapeutic approach for PCa patients with acquired Doc resistance. This evidence concerns the gene CCL5 and posterior cortical atrophy.